MA07.08 JIN-A02, a Highly Effective 4th Generation EGFR-TKI, Targeting EGFR C797S Triple Mutation in NSCLC

Among non-small cell lung cancer (NSCLC) gene mutations, epidermal growth factor receptor (EGFR) mutations are the most common and occur in approximately 50% of Asian NSCLC.1) Although EGFR-targeted therapeutics have been widely used for the treatment of EGFR-mutant lung cancer, acquired resistance invariably develops after 12-18 months in patients.2) EGFR C797S mutation, located within the tyrosine kinase domain, was recently reported to be a potential mechanism of resistance to irreversible EGFR inhibitors.